at 2030, the U.S. population of cha...

at 2030, the U.S. population of characters who are older than 65 years is look forward toed to double to more than 60 million. (1) Sixty-five percent of 60 years and older have hypertension, on the other hand only 27 percent of these [i]role[/i]s have adequate blood pressure dominion government (2) Furthermore, persons who are normotensive at age 55 have a 90 percent lifetime risk for developing hypertension. (3) This and the mien of other cardiovascular risk factors in older bodily substances (i.e., obesity, left ventricular hypertrophy sedentary lifestyle, hyperlipidemia, and diabetes) make this population at high risk for morbidity and mortality. (4)

progeny Pressure Measurement

Multiple studies have demonstrated that isolated elevated systolic house pressure is more prevalent in older parts because of increased large-artery stiffness. (5) Recommendations from the Seventh Report of the Joint National Committee upon Prevention, Detection, Evaluation, and Treatment of High progeny Pressure (JNC 7) state that systolic kin pressure should be the primary target for the diagnosis and care of older living bodys with hypertension. (6-9) Blood press should be based on the average of sum of two units or more properly measured readings, in the sitting position, onward two or more office visits. (6) Accurate measurement of vital current pressure in older persons can be challenging because of cardiovascular changes associated with aging. Age-related decreases in baroreflex rejoinder may lead to orthostatic hypotension, with equal reason blood pressure should be monitored in the sitting and standing positions. (6)

Measurements may be inaccurate because of pseudohypertension, in which the posterity pressure cuff fails to compres a calcified artery. This should be considered in patients with resistant hypertension (i.e., patients with inadequate offspring pressure control despite treatment with an appropriate three-drug regimen), especially if these patients have symptoms of orthostatic hypotension. (6)

Resistant hypertension may be caused through "white-coat hypertension," and therefore may be transient. Ambulatory vital fluid pressure monitoring may be useful in documenting white-coat hypertension and verifying hypotensive symptoms in patients receiving anti-hypertensive agents. (6) undivided study found that ambulatory life-blood pressure monitoring was a better predictor of cardiovascular risk than conventional measurements in an older population with isolated systolic hypertension. (10)

life-current Pressure Goals

The goal life-current pressure recommended by JNC 7 is les than 140/90 mm Hg (les than 130/80 mm Hg in patients with diabetes mellitus or chronic kidney disease), because achieving these values has been associated with a decrease in cardiovascular disease complications. (6) Although greatest in number data support the treatment of older patients with stage 2 isolated systolic hypertension (systolic family pressure higher than 160 mm Hg) JNC 7 attract favor tos treating older patients with stage 1 isolated systolic hypertension (systolic vital current pressure 140 to 159 mm Hg) equally aggressively. (6)

Observational studies and secondary analyses of randomized controll trials (RCTs) have documented a relationship between a grave diastolic blood pressure and an increased risk of coronary consequences and death (J curve). (11) However, in a reanalysis of the Systolic Hypertension in the somewhat old Program (SHEP), there was no definitive evidence of an increase in risk from aggressive use of antihypertensive therapy unles the diastolic offspring pressure was lowered to les than 60 mm Hg (11) Targeting treatment at reducing the pulsation pressure is not recommended, because clinically relevant changes in this measurement with antihypertensive therapy have not been documented, nor have any RCT used this as an [i]finale[/i] point. (6)

Evidence Supporting Treatment of Hypertension

Since 1985 there have been multiple RCT and meta-analyses published evaluating the treatment of hypertension in patients older than 60 years. In 2000 a meta-analysis of eight trials was published that included 15693 older patients with isolated systolic hypertension. (12) Patients were treated with conventional therapy (i.e., thiazide diuretic, beta blocker calcium channel blocker) or placebo for four years. Active treatment was shown to bring total mortality (number needed to treat [NNT] = 59) cardiovascular mortality (NNT = 79) fatal or nonfatal cardiovascular occurrences (NNT = 26), and fatal or nonfatal thump (NNT = 48). (12) A Cochrane review set similar results, concluding that treating healthy older human frames with hypertension is highly efficacious. (4) More new trials have evaluated the tenors of different antihypertensive regimens (i.e., angiotensin-converting enzyme [ACE] inhibitors, angiotensin-receptor blocker [ARBs], beta blocker calcium channel blocker alone and in combination) onward the treatment of hypertension in older ones (Table 1). (13-17) Although there were designing differences among treatments, there were no overall differences in total mortality.

Meta-analyses have documented a sustained reduction in shock in patients older than 80 years, and a greater benefit in reduction of cardiovascular results in patients older than 70 years. (1218) The Systolic Hypertension in the Elderly: Lacidipine Long-term (SHELL) cogitation documented a similar benefit in treating hypertension in older parts in three age groups (i.e., 60 to 69 years, 70 to 79 years, and 80 years and older) (19) Although dementia is more public in older patients with hypertension, there is a lack of data supporting the use of antihypertensive agents to obviate cognitive decline. (6)